Objective: Osteonecrosis is a serious comorbidity in patients with systemic lupus erythematosus. The aims of this study were to describe the prevalence of symptomatic osteonecrosis, determine the pattern of joint involvement, identify the outcomes and investigate predictive factors in a large cohort of patients with systemic lupus erythematosus followed prospectively. Methods: At the Toronto Lupus Clinic patients have been followed prospectively according to a standard protocol since 1970. Osteonecrosis is recorded if patients are symptomatic and is confirmed by imaging. The site of osteonecrosis is recorded and whether or not surgery was performed. For determination of prevalence, pattern and outcome of osteonecrosis a longitudinal cohort design was performed. For the predictive factors, only patients with incident osteonecrosis were included and were matched for gender, year of entry to clinic (within 5 years), year of birth (within 5 years) and disease duration (within 3 years) with systemic lupus erythematosus patients without osteonecrosis. Results: Of 1729 patients with systemic lupus erythematosus registered in the database, 234 (13.5%) developed symptomatic osteonecrosis in 581 sites. Hips and knees were most commonly affected and 47% of the patients had multiple sites involved. More than half of the joints involved at first occurrence of osteonecrosis had surgery. Univariate analysis identified black race, damage, elevated cholesterol and glucocorticosteroids as predictive factors, but glucocorticosteroids remained as the primary predictor for the development of osteonecrosis on multivariable analysis. Conclusion: Despite advancements in the assessment and treatment of systemic lupus erythematosus, symptomatic osteonecrosis continues to be a significant comorbidity. Strategies to minimize glucocorticosteroid use are necessary to prevent this serious complication. Lupus (2018) 27, 76-81.
Introduction
Osteonecrosis is a serious comorbidity of systemic lupus erythematosus (SLE). The reported prevalence of symptomatic osteonecrosis in SLE varies between 4% and 15% but can be up to 40% when asymptomatic patients are included. 1, 2 Osteonecrosis in SLE has been shown to be a significant cause of morbidity among SLE patients, significantly affecting function and quality of life. 3 Multiple studies have shown that corticosteroids are the major cause of osteonecrosis in SLE. 2, 4 We have previously demonstrated in a nested case-control study that when patients with osteonecrosis were matched on steroid dose to those without osteonecrosis, no other risk factors were identified for the development of symptomatic osteonecrosis. 2 The majority of the studies are small with the largest being less than 100 patients.
The aims of this study were to describe the prevalence of symptomatic osteonecrosis, determine the pattern of joint involvement, identify the outcomes and investigate predictive factors in a large cohort of patients with SLE followed prospectively in a single centre.
Methods

Setting
The University of Toronto Lupus Clinic has been following patients with SLE prospectively since 1970. Only patients meeting at least four American College of Rheumatology (ACR) criteria of SLE or three criteria and biopsy confirmed lupus are enrolled. Ethics approval for the collection of clinical, laboratory and imaging data has been approved by the University Health Network Research Ethics Board and guidelines for patient consent have been met.
Assessments
Patients are followed every 2-6 months, using a standardized protocol which includes a complete history, physical examination and laboratory evaluation. All data are collected and stored in an Oracle database. Disease activity is measured by the systemic lupus erythematosus disease activity index (SLEDAI-2K), 5 and damage is evaluated using the Systemic Lupus International Collaborating Clinics (SLICC)/ACR damage index (SDI). 6 
Study design
Part I: For the prevalence, patterns and outcome, a longitudinal cohort study was carried out. Part II: For the assessment of predictive factors, a nested case-control design was used.
Patient selection
For part I all SLE patients with osteonecrosis were identified from the Lupus Clinic database. For part II, SLE patients who developed osteonecrosis only after clinic entry were identified. Cases were matched to control SLE patients by: gender, year of entry to clinic (within 5 years), year of birth (within 5 years) and disease duration (within 3 years).
Outcome
Osteonecrosis was defined as clinical symptoms and was confirmed by imaging (x-ray, bone scan, computed tomography, MRI).
Predictive factors
Clinical, laboratory and therapeutic variables were included as predictors. We included antiphospholipid antibodies (aPL) and further defined antiphospholipid syndrome (APS) as: two or more lupus anticoagulant (LA) or anticardiolipin antibody (aCL) positive tests separated by at least 12 weeks, plus one of the following clinical manifestations: (a) thrombotic events; (b) pregnancy events -spontaneous abortions three or more times or stillbirth or premature birth.
Statistical analysis
Part I: Descriptive statistics were used.
Incidence rates were calculated by dividing newly diagnosed osteonecrosis by the number of patientyears followed in each decade. Demographics, disease activity, organ damage and treatments were described by means þ SD or count (percentage) depending on the nature of the measures as continuous or categorical variables.
Part II: Univariate conditional logistic regressions were carried out on each potential predictive factor. Variables meeting P value less than 0.2 on univariate analysis, or clinically regarded as important risk factors, were selected for multivariable regression analysis. The Akaike information criterion (AIC) was adopted as the method of assessing the goodness of fit. Age at osteonecrosis, black race, steroid-related SLICC damage, mean total cholesterol 3 years prior to osteonecrosis or last visit, mean steroid dose, cumulative steroid dose and mean duration of immunosuppressant use were included in the multivariable analysis.
Results
Part I: Of 1729 patients with SLE registered in the database, 234 (13.5%) developed symptomatic osteonecrosis (Table 1) . Looking at incidence rates by decade there seems to be a decreased incidence rate from 0.14 in the 1970s, to 0.06 in the 1980s, to 0.04 in 
Pattern of joint involvement with osteonecrosis
A total of 541 joints with symptomatic osteonecrosis were identified, in which 381 joints were affected at the time of first osteonecrosis diagnosis. The distribution of joints involved at the first time of osteonecrosis diagnosis is depicted in Figure 1 . As can be seen the majority were hip joints followed by knees, with other joints less common. There were 160 additional joints with osteonecrosis which developed subsequently. One hundred and eleven of the 234 patients (47.4%) had multiple site involvement at first osteonecrosis event. The mean number of osteonecrosis joints per person was 1.6 AE 0.9, and the number with two, three, four, five and six joints involved were 94, four, nine, two and two patients, respectively.
Outcomes
Patients with osteonecrosis were followed for a mean AE SD of 9.0 AE 7.7 years to the last visit, or 4.0 AE 5.7 years to surgery based on the first occurrence of osteonecrosis. Of the joints involved at the time of first osteonecrosis diagnosis those that progressed to surgical intervention (N ¼ 152) included 131 of 244 hips, 18 of 86 knees, one of three wrists, one of 28 shoulders, none of 15 ankles, none of two elbows and one of three other joints (Figure 2 ). The mean time from osteonecrosis diagnosis to surgical intervention of the hip was 3.7 AE 5.2 years and of the knee 5.5 AE 6.2 years. The mean follow-up from SLE diagnosis to first osteonecrosis of 229 patients not going on to surgery was 8.3 AE 8.5 years. Part II: Predictive factors. Of the 234 patients in part II, 171 cases of newly diagnosed symptomatic osteonecrosis after entry to the Lupus Clinic were identified. One hundred and sixty-two were successfully matched to controls ( Table 2 ). In the univariate analysis the following variables achieved a P value less than 0.2: age at osteonecrosis or last visit (P ¼ 0.08), black race (P ¼ 0.03), SDI related to glucocorticosteroids (P ¼ 0.05), mean total cholesterol 3 years prior to osteonecrosis or last visit (P ¼ 0.03), average glucocorticosteroids dose (P ¼ 0.0002) and duration on immunosuppressives before osteonecrosis or last visit (P ¼ 0.09). Importantly, neither aPL nor APS were significantly different between cases and controls. Multivariable analysis, looking for predictors for the development of osteonecrosis, identified only mean glucocorticosteroid dose to osteonecrosis or last visit as a predictor for osteonecrosis (Table 3) . Osteonecrosis occurred at doses as low as 10 mg per day. The median duration on glucocorticosteroids at the time of osteonecrosis was 3.4 years.
Discussion
The prevalence of osteonecrosis and its predictive factors have varied in reported series. In childhood SLE the prevalence of symptomatic osteonecrosis was 6%. 7 Risk factors were major organ involvement including the central nervous system and nephritis and maximal corticosteroid dose. A systematic review of osteonecrosis in a number of conditions included some patients with SLE. There was a strong correlation between glucocorticosteroid dose and osteonecrosis rate such that for each 10 mg/day of glucocorticosteroids, there was a 3.6% increase in the osteonecrosis rate. In a retrospective observational study of 158 patients with SLE 9.5% developed osteonecrosis. Osteonecrosis was associated with Cushing's syndrome and accumulated damage at year 2.
9
A study from Korea including 25,358 patients with SLE reported that the prevalence of osteonecrosis between 2006 and 2010 was 31.5-34.2 per 1000 persons. A standardized annual incidence rate of 7.6-9.2 per 1000 was calculated between 2008 and 2010. Osteonecrosis was associated with the use of glucocorticosteroids, immunosuppressive agents, hydroxychloroquine, lipid-lowering agents and hypertension. 10 Lee et al. reviewed the medical records of 1051 patients with SLE of whom 73 had symptomatic osteonecrosis (6.9%).
11 Independent risk factors for the development of symptomatic osteonecrosis were Cushingoid habitus and the use of cyclophosphamide and azathioprine. The prevalence of osteonecrosis in Thai lupus patients was reported at 8.8%. Haematological involvement and long duration of disease predicted osteonecrosis. 12 A Turkish study reported the prevalence of osteonecrosis in lupus patients was 6%, 13 whereas a study from Dubai found osteonecrosis in 8.7% of lupus patients (Table 4) . 14 To our knowledge ours is the largest cohort of SLE patients with symptomatic osteonecrosis studied to date. Among 1729 SLE patients 235 (13.6%) developed symptomatic osteonecrosis. The prevalence of osteonecrosis in our study is higher than generally reported. This may be due to the longitudinal nature and the long duration (40 plus years) of our cohort.
On average, osteonecrosis in our cohort occurred 8.2 AE 8.1 years after the initial SLE diagnosis. Approximately half of the patients (47.2%) had multiple site involvement on the first osteonecrosis diagnosis. As reported in most other series, large weight-bearing joints, including the hip and knee, were most frequently involved. Hips most frequently required surgical intervention.
The predictive factors for osteonecrosis vary in studies, but glucocorticosteroids appear to be important in the majority of the studies that performed multivariable analyses. Despite the large number of SLE patients with osteonecrosis in this study, we are still finding that only glucocorticosteroids remained in the multivariable analysis as the primary predictor for the development of osteonecrosis. In our study, it would seem that any dose of glucocorticosteroids may predispose to osteonecrosis, as doses as low as 10 mg per day were associated with osteonecrosis. The median duration of glucocorticosteroid use prior to the development of osteonecrosis was 3.4 years, suggesting that even a short exposure in some patients may be associated with osteonecrosis. Moreover, two of our patients had not received oral or parenteral glucocorticosteroids prior to their osteonecrosis; however, both patients had extensive skin involvement as their major lupus manifestations and used high doses and long durations of topical corticosteroids. When we evaluated the incidence of osteonecrosis over the decades we noted a decreased incidence rate from 0.14 in the 1970s to 0.02 in the current decade, possibly related to the decreased use of high dose glucocorticosteroids. Possible explanations for the development of osteonecrosis among patients taking glucocorticosteroids include subchondral osteoporosis, with subsequent microfracture, vasculitis, or venous thrombosis from predispositions such as APS. However, in our study neither aPL nor APS were identified as predictors for osteonecrosis.
However, it is not clear why some patients who have the same risk factor, that is taking glucocorticosteroids, do not develop osteonecrosis. Thus individual end organ sensitivity is an important risk factor for the development of osteonecrosis, the nature of which requires further study. Also, why osteonecrosis heals in some patients and results in collapse in others is not clear.
In conclusion, despite advancements in the assessment and treatment of SLE, symptomatic osteonecrosis continues to be a significant comorbidity. Strategies to minimize glucocorticosteroid use are necessary to prevent this serious complication.
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